Pages that link to "Q37346420"

The following pages link to Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines (Q37346420):

Displaying 36 items.

• A global approach to HIV-1 vaccine development (Q27024614) (← links)
• Use of an in vivo FTA assay to assess the magnitude, functional avidity and epitope variant cross-reactivity of T cell responses following HIV-1 recombinant poxvirus vaccination (Q27314609) (← links)
• Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone (Q28535477) (← links)
• The Number and Complexity of Pure and Recombinant HIV-1 Strains Observed within Incident Infections during the HIV and Malaria Cohort Study Conducted in Kericho, Kenya, from 2003 to 2006 (Q28608652) (← links)
• New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics. (Q30393882) (← links)
• AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines (Q30394227) (← links)
• Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications (Q30410411) (← links)
• Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines (Q33653229) (← links)
• Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate (Q33749950) (← links)
• HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV. (Q33869332) (← links)
• Dual neonate vaccine platform against HIV-1 and M. tuberculosis (Q33908584) (← links)
• Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models (Q34046006) (← links)
• The use of fluorescent target arrays for assessment of T cell responses in vivo (Q34331731) (← links)
• Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens (Q34438489) (← links)
• Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2 (Q34673436) (← links)
• Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching (Q34810232) (← links)
• Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia (Q35075505) (← links)
• Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial (Q35431516) (← links)
• HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial (Q35677513) (← links)
• Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge (Q35883032) (← links)
• Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania (Q36697992) (← links)
• Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants (Q37209483) (← links)
• Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees (Q37610683) (← links)
• Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors (Q38176419) (← links)
• Peptide-MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development (Q38265356) (← links)
• The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. (Q38725610) (← links)
• Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen (Q38897238) (← links)
• Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses (Q39703820) (← links)
• Intradermal HIV-1 DNA immunization using needle-free Zetajet^TM injection followed by HIV-modified vaccinia virus Ankara vaccination is safe and immunogenic in Mozambican young adults: a phase I randomized controlled trial. (Q41926279) (← links)
• Safety and Immunogenicity of PENNVAX®-G DNA Prime Administered by Biojector® 2000 or CELLECTRA® Electroporation Device with Modified Vaccinia Ankara-CMDR Boost (Q41926555) (← links)
• Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag. (Q42198238) (← links)
• Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. (Q51830138) (← links)
• Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design (Q59349567) (← links)
• Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence (Q64093092) (← links)
• An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design (Q91813907) (← links)
• A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge (Q92987631) (← links)